Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty.

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock ...

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has declined 5.8% over the past month. However, a closer look at its sound financials ...

Abbott posted Q2 revenue of $11.14 billion and EPS of $1.26, raised 2025 earnings guidance, and saw strong growth in diabetes and heart device sales.

The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% ...

Jayson Bedford from Raymond James set a target price of $142.0 on 04/17/2025 $ABT Congressional Stock Trading Members of Congress have traded $ABT stock 13 times in the past 6 months.

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Conversely, if the dividend payment decreases, so will the yield. ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on Monday. Read More: ...